微生态制剂治疗肝硬化的Meta分析

孙元培; 郭晓霞

doi:10.3969/j.issn.1001-5256.2018.01.015

微生态制剂治疗肝硬化的Meta分析

DOI: 10.3969/j.issn.1001-5256.2018.01.015

1. 山西省中医药研究院
2. 山西省中医院肝病科

基金项目:

山西省重点研发计划项目(201603D321042)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2026
- HTML全文浏览量: 65
- PDF下载量: 493
- 被引次数: 3
出版历程
- 出版日期: 2018-01-20

Clinical effect of probiotics in treatment of liver cirrhosis: a Meta-analysis

Shanxi Research Institute of Traditional Chinese Medicine, Taiyuan 030012, China

Research funding:

摘要

摘要:
目的系统评价微生态制剂治疗肝硬化的有效性。方法计算机检索PubMed、Embase、Cochrane Library以及中国期刊全文数据库、维普、万方数据库,全面收集关于微生态制剂治疗肝硬化的随机对照试验,筛选后的文献应用Rev Man5.3软件进行Meta分析,其中二分类变量采用率差（RD）及其95%可信区间（95%CI）作为效应量;连续性变量若测量单位一致则采用加权均数差（WMD）,测量单位不一致采用标准化均数差（SMD）及其95%CI进行评估。发表偏倚采用漏斗图进行分析。结果纳入符合标准的文献18篇,共1411例肝硬化患者,其中治疗组726例,对照组685例。与对照组相比,微生态制剂治疗可显著提高临床总体有效率（RD=0.28,95%CI:0.220.34,P<0.001）;亦可以明显改善肝功能生化指标:ALT（SMD=-0.90,95%CI:-1.14-0.66,P<0.001）、TBil（WMD=-15.99,95%CI:-26.42-5.57,P<0.001）、Alb（SMD=0.66,95...
- 肝硬化 /
- 微生态制剂 /
- 治疗 /
- Meta分析
Abstract:
Objective To investigate the clinical effect of probiotics in the treatment of liver cirrhosis through a systematic review. Methods PubMed, Embase, Cochrane Library, Chinese Scientific Journal Full-Text Database, VIP, and Wanfang Data were searched for randomized controlled trials ( RCTs) of probiotics for the treatment of liver cirrhosis. Rev Man 5. 3 software was used for the meta-analysis of the articles screened out. Rate difference ( RD) and its 95% confidence interval ( 95% CI) were used as effect size indicators for binary variables; weighted mean difference ( WMD) was used for evaluating continuous variables with the same unit, and standardized mean difference ( SMD) and its 95% CI were used for evaluating continuous variables with different units. Funnel plots were used to analyze publication bias.Results A total of 15 RCTs which met the inclusion criteria were included, and there were 1411 patients with liver cirrhosis in total ( 726 in treatment group and 685 in control group) . Compared with the control group, the treatment group had significant improvements in overall response rate ( RD = 0. 28, 95% CI: 0. 22-0. 34, P < 0. 001) and biochemical parameters for liver function including alanine aminotransferase ( SMD =-0. 90, 95% CI:-1. 14 to-0. 66, P < 0. 001) , total bilirubin ( WMD =-15. 99, 95% CI:-26. 42 to-5. 57, P <0. 001) , albumin ( SMD = 0. 66, 95% CI: 0. 40-0. 93, P < 0. 001) , endotoxin ( SMD =-1. 13, 95% CI:-2. 11 to-0. 15, P <0. 001) , and blood ammonia ( WMD =-15. 86, 95% CI:-21. 54 to-10. 18, P < 0. 001) . Conclusion Probiotics can significantly improve liver function in patients with liver cirrhosis, effectively inhibit the progression of liver cirrhosis, reduce the risk of complications including hepatic encephalopathy, and increase overall response rate and have good tolerability.
- liver cirrhosis /
- probiotics /
- therapy /
- Meta-analysis

HTML全文

参考文献(23)

[1]LI F, LI ZL, LIN BL, et al.Study on variation of lipidemia and apolipoprotein in posthepatitic cirrhosis and biliary cirrhosis[J].China J Modern Med, 2004, 14 (13) :52-54. (in Chinese) 黎芳, 黎志良, 林炳亮, 等.病毒性肝炎肝硬化与胆汁性肝硬化的血脂及载脂蛋白分析比较[J].中国现代医学杂志, 2004, 14 (13) :52-54.

[2]BIAN XP, JING JX.Clinical observation of treating hepatocirrhosis diahrrhea with micro-ecological production Miya-BM[J].Natl Med Front China, 2012, 7 (23) :31-32. (in Chinese) 卞孝平, 荆军祥.微生态制剂米雅治疗肝硬化腹泻临床观察[J].中国医疗前沿, 2012, 7 (23) :31-32.

[3]CHEN YP, ZHONG ZH, LIANG YH, et al.Effect of microbial ecological agent on the function of intestinal mucosa barrier in cirrhosis patients[J].Chin J Clin Gastroenterol, 2010, 22 (4) :204-207. (in Chinese) 陈渝萍, 钟转华, 梁月环, 等.微生态制剂对肝硬化患者肠屏障功能影响及疗效观察[J].临床消化病杂志, 2010, 22 (4) :204-207.

[4]PEREG D, KOTLIROFF A, GADOTH N, et al.Probiotics for patients with compensated liver cirrhosis:a double-blind placebocontrolled study[J].Nutrition, 2011, 27:177-181.

[5]DING GW, GAO CG.Clinical efficacy of Saccharomyces boulardii in treatment of diarrhea in patients with liver cirrhosis[J].Guide China Med, 2012, 10 (31) :243-244. (in Chinese) 丁光伟, 高春耕.布拉酵母菌治疗肝硬化腹泻的临床观察[J].中国医药指南, 2012, 10 (31) :243-244.

[6]FENG ZP, YE WS.Clinical observation of treating hepatocirrhosis diahrrhea with micro-ecological production P.O.Bifidobiogcn[J].J Trop Med, 2002, 2 (1) :52-53. (in Chinese) 冯正平, 叶伟生.微生态制剂丽珠肠乐治疗肝硬化腹泻临床观察[J].热带医学杂志, 2002, 2 (1) :52-53.

[7]BAJAJ JS, HEUMAN DM, HYLEMON PB, et al.Randomised clinical trial:Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J].Aliment Pharmacol Ther, 2014, 39 (10) :1113-1125.

[8]PANG CH.Efficacy of oral MIYA-BM tablets in treatment of non-infectious diarrhea in patients with liver cirrhosis[J].Strait Pharm J, 2012, 24 (12) :170-171. (in Chinese) 庞春红.口服米雅BM片治疗肝硬化非感染性腹泻的疗效观察[J].海峡药学, 2012, 24 (12) :170-171.

[9]SUN XH.The effects of probiotics on intestinal flora and cell-mediated immune function in patients with liver cirrhosis[J].China Mod Doct, 49 (18) :1-2, 11. (in Chinese) 孙晓晖.微生态制剂对肝硬化患者肠道菌群与细胞免疫功能的影响[J].中国现代医生, 49 (18) :1-2, 11.

[10]WAN W, ZHANG WL, ZHAO J.Influence to serum endotoxin and TNF-αin cirrhosis patients with beifeida therapy[J].J Clin Hepatol, 2005, 21 (2) :93-94. (in Chinese) 万巍, 张薇莉, 赵隽.贝飞达对肝硬化患者血浆内毒素及TNF-α的影响[J].临床肝胆病杂志, 2005, 21 (2) :93-94.

[11]WANG J, WANG ZY.Medilac-S in treatment of liver cirrhosis combined with spontaneous bacterial peritonitis[J].Occupation Health, 2008, 24 (23) :2610-2611. (in Chinese) 王静, 王震宇.美常安治疗肝硬化并自发性腹膜炎[J].职业与健康, 2008, 24 (23) :2610-2611.

[12]WANG XL.Efficacy of Bifidobacterium tetravaccine tablets in treatment of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].Chin J Clin Ration Drug Use, 2011, 4 (3A) :49-50. (in Chinese) 王秀丽.双歧杆菌四联活菌片治疗肝硬化自发性细菌性腹膜炎的疗效观察[J].临床合理用药杂志, 2011, 4 (3A) :49-50.

[13]YANG FT.Efficacy of probiotic preparation in treatment of liver cirrhosis[J].Clin Res Pract, 2016, 1 (20) :80-81. (in Chinese) 杨飞童.益生菌抑剂治疗肝硬化的观察[J].临床医学研究与实践, 2016, 1 (20) :80-81.

[14]ZHANG BJ, NIU XF, WANG QZ.Efficacy of Golden Bifid in treatment of liver cirrhosis with spontaneous peritonitis[J].J Medical Forum, 2007, 28 (24) :107-111. (in Chinese) 张帮杰, 牛秀峰, 王庆治.金双歧治疗肝硬化并自发性腹膜炎[J].医药论坛杂志, 2007, 28 (24) :107-111.

[15]ZHAO JM, HU RX, ZHU Q.Efficacy of microecologics in treatment of diarrhea in patients with liver cirrhosis:a report of 56 cases[J].J Clin Med Pract, 2010, 14 (1) :67-70. (in Chinese) 赵坚敏, 胡荣昕, 朱琦.微生态制剂治疗肝硬化腹泻56例临床观察[J].实用临床医药杂志, 2010, 14 (1) :67-70.

[16]ZHENG SJ, WANG CH, ZHAN GQ.Efficacy of microbioecologics in hepatic cirrhosis patients with spontaneous bacterial peritonitis[J].Chin J Microecol, 2014, 26 (1) :62-65. (in Chinese) 郑三菊, 王崇慧, 占国清.微生态制剂治疗肝硬化自发性细菌性腹膜炎疗效观察[J].中国微生态学杂志, 2014, 26 (1) :62-65.

[17]DHIMAN RK, RANA B, AGRAWAL S, et al.Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis:a randomized, controlled trial[J].Gastroenterology, 2014, 147 (6) :1327-1337.

[18]LUNIA MK, SHARMA BC, SHARMA P, et al.Probiotics prevent hepatic encephalopathy in patients with cirrhosis:a randomized controlled trial[J].Clin Gastroenterol Hepatol, 2014, 12 (6) :1003-1008.

[19]AGRAWAL A, SHARMA BC, SHARMA P, et al.Secondary prophylaxis of hepatic encephalopathy in cirrhosis:an open-label, randomized controlled trial of lactulose, probiotics, and no therapy[J].Am J Gastroenterol, 2012, 107 (7) :1043-1050.

[20]WEI X, YAN XB, ZOU DY, et al.Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J].BMC Gastroenterlogy, 2013, 13:175.

[21]ZHANG SR.Curative effects of probiotics combined with adefovir dipivoxil in treatment of HBV-related cirrhosis and the effects on immune function[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :44-47. (in Chinese) 张世睿.微生态制剂联合阿德福韦酯治疗慢性乙型肝炎肝硬化的疗效及对机体免疫功能的影响[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :44-47.

[22]BAJAJ JS, RIDLON JM, HYLEMON PB, et al.Linkage of gut microbiome with cognition in hepatic encephalopathy[J].Am J Physiol Gastrointest Liver Physiol, 2012, 302 (1) :g168-g175.

[23]PANDE C, KUMAR A, SARIN SK.Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis:a double-blind placebo-controlled randomized-controlled trial[J].Eur J Gastroenterol Hepatol, 2012, 24 (7) :831-839.

施引文献

期刊类型引用(2)

1.	高毓慷，钱瑞坤，马长林，乔森. ICG-R15联合三维影像重建技术在肝癌术前评估的临床研究. 重庆医学. 2024(02): 257-263 . 百度学术
2.	施舒鹏，常久翔，曾陶飞，何浩，尹大龙. 基于Cite Space文献计量法肝癌微创治疗的可视化分析. 中华消化外科杂志. 2023(09): 1139-1146 . 百度学术